including those of a new class and a new generation of an existing class. Caspofungin, the first available echinocandin, has greatly expanded the antifungal armamentarium by providing a cell wall-active agent with candidacidal activity as well as demonstrated clinical efficacy in the therapy of aspergillosis refractory to available therapy. In addition, in clinical trials, caspofungin had comparable efficacy to amphotericin B for candidaemia and invasive Candida infections. Caspofungin and two more recently introduced echinocandins, micafungin and anidulafungin, are available as intravenous formulations only and characterised by potent anti-candidal activity, as well as few adverse events and drug interactions.
Both the frequency and severity of invasive fun-80-100% in high-risk patients, including those with gal infections in immunocompromised patients has underlying haematological malignancy, bone marincreased steadily over the past two decades. Mor-row or solid organ transplantation. [1] [2] [3] [4] Apart from tality due to invasive aspergillosis approaches organ transplant recipients, individuals with AIDS and patients hospitalised with severe illnesses, maCell wall-active agents include echinocandin lijor increases in invasive fungal infections have been popeptides and the nucleoside-peptide antibiotic observed in patients with haematological malignan-nikkomycin Z. [11] cies who receive induction or consolidation chemotherapy and those who undergo bone marrow trans-
Echinocandin Lipopeptides
plantation. [5] [6] [7] [8] Echinocandins are natural cyclic hexapeptide This review focuses on newer antifungal agents, antifungal compounds that noncompetitively inhibit specifically the second-generation triazoles, vori-1,3 β-D-glucan synthase, an enzyme complex that is conazole, posaconazole and ravuconazole, and the unique to a number of fungi, which forms glucan echinocandins, caspofungin, micafungin and anidupolymers in the fungal cell wall. [12] Echinocandins lafungin (table I). The objective of the article is to are active against Candida spp. and Pneumocystis update the previous review published in 2001 , [9] jiroveci (formerly known as P. carinii). Specific focusing on the most recent additions to the antimodifications to the N-acyl aliphatic or aryl side fungal armamentarium. Data regarding overall prochains expand the antifungal spectrum to include file, in vitro and in vivo activity, pharmacokinetics Aspergillus spp. [12, 13] and tissue distribution, as well as published clinical Caspofungin (formerly L-743872, MK-0991) efficacy and safety data, are presented for each of is the only US FDA-approved echinocandin, these newer agents.
while micafungin (FK-463) and anidulafungin (LY 303366, VER-002) are under review. All three
Cell Wall Synthesis Inhibitors
echinocandins have poor bioavailability and are curDevelopers of antifungal agents followed the rently available only in intravenous formulation lead of their antibacterial drug development col-(figure 1). Thus far, all three have been associated leagues in seeking drugs active against components with few drug interactions and good to excellent of the fungal cell wall. Disruption of the fungal cell tolerability in clinical trials. Caspofungin is currentwall leads to osmotic stress, lysis and fungal cell ly approved by the US FDA for use in treatment of death. [10] For most fungi, key cell wall elements candidaemia and salvage therapy of invasive asperinclude chitin, β-or α-linked glucans and various gillosis. mannoproteins. As these are unique to fungi and not
Caspofungin
found in human cells, agents active at these sites are particularly attractive targets and pose a low risk of
The first approved echinocandin, caspofungin, is mechanistic toxicity. a semisynthetic derivative of pneumocandin B0, a 
Antifungal compounds targeting fungal cell membrane

Polyene antifungals
Amphotericin B Interaction with ergosterol, formation of aqueous channels, increased membrane Lipid formulations of amphotericin B permeability to univalent and divalent cations, cell death
Antifungal triazoles
Fluconazole Interaction with cytochrome P450; inhibition of C-14 demethylation of lanosterol, Itraconazole causing ergosterol depletion and accumulation of aberrant and toxic sterols in the Voriconazole cell membrane Posaconazole Ravuconazole
Antifungal compounds targeting fungal cell wall
Echinocandins
Caspofungin
Inhibition of fungal β-(1,3) glucan synthase complex, leading to depletion of cell-wall Micafungin glucan and osmotic instability Anidulafungin fermentation product of Glarea lozoyensis. Cas-following therapy and increased galactomannan pofungin is a water-soluble amphipathic lipopeptide antigenaemia with therapy. [32] Fragmentation of hythat is available in an intravenous formulation only. phal elements, particularly at branch points, damDeresinski and Stevens [10] have recently published ages mycelium and leads to an increase in the numan extensive review of caspofungin.
ber of viable mycelial units. These mycelia are damaged when examined via electron microscopy
In Vitro Activity and exhibit reduced propensity for angioinvasion in Caspofungin is fungicidal in vitro against Candi-vitro and in vivo. This allows for improved survival da spp., [14] including azole-resistant Candida, [15] and and ultimately eradication. Quantitative polymerase has potent activity in vitro against Aspergillus spp. chain reaction analyses demonstrate a reduction in and some dimorphic moulds, such as Histoplasma overall viable fungal burden. [33] 
capsulatum, Coccidioides immitis and Blastomyces
In a model of invasive aspergillosis in immudermatitidis. Cryptococcus neoformans is relatively nosuppressed guinea pigs, caspofungin in combinaresistant to caspofungin, as are several yeasts in-tion with voriconazole was associated with a morcluding Trichosporon spp. and Rhodotorula tality benefit similar to that of voriconazole alone, spp. [16, 17] but the combination resulted in a reduced total numActivity in vitro is somewhat less against C. ber of positive cultures from any organ tested, inparapsilosis, C. lusitaniae and C. guilliermondi than cluding the important sites of brain, lung, liver and against other Candida spp. [16, 18] In vitro studies have kidney. [34] This study and subsequent in vivo studies demonstrated no cross-resistance to azoles. [15] provide a rationale for testing the hypothesis of Caspofungin has demonstrated activity against combination therapy for invasive aspergillosis in Aspergillus spp. In multiple studies, caspofungin clinical trials. [35] has proven additivity or synergy with other azoles Caspofungin was studied alone and in combinaand amphotericin B, as well as calcineurin inhibi-tion with amphotericin in a murine model of coctors, versus Aspergillus spp. [14, [19] [20] [21] [22] [23] Caspofungin has cidioidomycosis. [36] In the initial study, caspofunlimited in vitro activity against other moulds, in-gin, amphotericin B and liposomal amphotericin B cluding Fusarium spp., Scedosporium spp., zygo-were all associated with longer survival and demycetes, Pseudallescheria boydii or dematiaceous creased residual fungal burden. In the combination moulds.
[16, [24] [25] [26] study, all treatments significantly prolonged survival and effectively decreased residual fungal burden
In Vivo Activity in spleen and liver. Importantly, the combination of Caspofungin has been extensively studied in caspofungin and liposomal amphotericin B was animal models of invasive fungal infection, includassociated with 100% sterilisation of the spleen and ing in severely immunocompromised animals. In liver.
[36]
studies of invasive Candida infection in mice, including those due to fluconazole-resistant organisms
Pharmacokinetics and Tissue Distribution (C. krusei, C. glabrata, etc.), caspofungin effectively prolonged survival, decreased fungal burden in Like other echinocandins, caspofungin has low target organs and sterilised kidneys in significant oral bioavailability and, thus, is available only in the numbers of animals, even in the presence of neutro-intravenous formulation. The drug is highly protein penia. [27] [28] [29] [30] [31] In a murine model of cryptococcosis, bound (>95%) with extensive distribution into caspofungin was ineffective. [14, 27] animal tissues, including brain (although concentraCaspofungin demonstrated a survival advantage tions are lower in brain and cerebrospinal fluid and reduction in organism-mediated pulmonary in-[CSF] of animals with uninflamed meninjury in a neutropenic rabbit model of invasive asper-ges). [17, 37, 38] Caspofungin is thought to undergo hepgillosis. [32] While caspofungin therapy was asso-atic metabolism via spontaneous peptide hydrolysis ciated with concentration-and dose-dependent hy-and N-acetylation. The major degradation product phal damage, rabbits treated with caspofungin had a has no antifungal activity and, thus, is not believed paradoxical trend toward increased fungal burden to contribute to clinical efficacy. [39, 40] The drug is not removed with haemodialysis and no dose adjust-bamazepine. Patients who require caspofungin ments are recommended for renal insufficiency or along with these medications should receive casfailure requiring haemodialysis. [39, 40] Phase I studies pofungin 70 mg/day. [39, 40] Nelfinavir demonstrated demonstrated that plasma caspofungin concentra-no significant effect on the plasma pharmacotions increase with moderate hepatic insufficiency kinetics of caspofungin and no dose adjustment is (Child-Pugh score 7-9). Consequently, the US recommended. [44] In the same study, rifampin both FDA-approved US Package Insert (USPI) recom-inhibited and induced caspofungin disposition, remends using the standard loading dose (70mg) fol-sulting in decreased serum concentration 24-hours lowed by a reduced daily dose of 35mg in patients post-dose (C24h), i.e. decreased exposure to caswith moderate hepatic impairment. Radiolabel stud-pofungin, at steady state. Thus, consideration of ies demonstrated that 41% of the dose of cas-increasing the caspofungin dose to 70 mg/day pofungin is excreted in the urine and 35% in fae-should be given when concomitant administration of ces. [41] rifampin is necessary. [44] Pharmacokinetics of caspofungin are linear with an elimination half-life (t 1 /2β) between 10 and 15 Clinical Efficacy hours, allowing for once daily dose administraCaspofungin was approved for marketing in the tion. [37, 42] A 70mg loading dose leads to mean US based on the demonstration of efficacy in the steady-state concentrations above 1 μg/mL at day 1; treatment of 56 patients with invasive aspergillosis similar to those at day 14 when 50 mg/day is given refractory to standard therapy. In these well docuwithout a loading dose. [10, 42] This, along with the mented cases, caspofungin therapy was associated serious nature of the infections caspofungin is used with success (complete or partial responses) in 41% to treat, led to the recommendation for a standard of the patients.
[39] A recent update of this study loading dose of 70mg. The plasma pharmaco-reported on a total of 90 patients and, again, success kinetics of caspofungin in children are different was seen in 45% of patients. [45] This is the same from those of adults. In order to achieve comparable success rate demonstrated for several of the lipid drug exposure, 50 mg/m 2 /day is recommended for formulations of amphotericin B in the salvage setpaediatric patients who are greater than 2 years of ting. age. [43] Caspofungin has been studied extensively in Caspofungin was studied with several drugs in candidal infections. Caspofungin has demonstrated phase I drug interaction studies. Despite the fact that efficacy compared with amphotericin B deoxychocaspofungin does not appear to inhibit P-glycoprote-late for endoscopically proven oesophageal candiin or hepatic cytochrome P450 (CYP) enzymes in diasis [46] and successful treatment of refractory vitro, several significant interactions were observed candidal infections, including a case of hepatosplenin these studies. Ciclosporin (cyclosporine) in-ic candidiasis refractory to amphotericin B deoxycreased the area under the plasma concentration-cholate. [47] Most recently, results of an international time curve (AUC24) of caspofungin by 35%. [39, 40] In randomised, double-blind study of caspofungin verone study, several healthy volunteers who received sus amphotericin B deoxycholate for treatment of caspofungin in combination with ciclosporin devel-invasive candidiasis supported the licensure of casoped transient increases in alanine aminotransferase. pofungin for therapy of candidaemia and intra-abdoThus, the USPI warns against using caspofungin minal infections, abscesses, peritonitis and pleural with ciclosporin unless the benefits outweigh the space infections due to Candida spp.
[48] Of note, this risks. [40] No significant interactions between cas-trial included non-albicans Candida isolates from pofungin and amphotericin B, itraconazole, 2-hy-over 50% of the caspofungin patients, the vast madroxy-itraconazole or mycophenolate were observ-jority of whom had successful outcomes. A noteed in phase I studies. [39] worthy exception was the C. parapsilosis group. Reductions in serum caspofungin concentrations Approximately 20% of patients in each treatment (AUC) were seen in the presence of efavirenz, nevi-arm had C. parapsilosis isolated at baseline. Five rapine, rifampin, dexamethasone, phenytoin or car-caspofungin-treated patients had persistently posi-tive blood cultures for C. parapsilosis compared Trichosporon spp., or zygomycetes. [53, 55] In vitro with no amphotericin B recipients. An accompany-testing was also conducted on dimorphic fungi, with ing editorial noted the relationship to the higher focus on its differential effects on yeast-like and minimum inhibitory concentrations (MICs) for mycelial forms, and micafungin was shown to have C. parapsilosis and the need for close monitoring potent activity against the mycelial form of H. capfor persistent fungaemia. [13] sulatum, B. dermatitidis, and C. immitis, but no activity against the yeast forms. [56] Caspofungin was comparable with liposomal amphotericin B in the, to date, largest international,
In vitro combination studies of micafungin with double-blind, multicentre study of empirical anti-other echinocandins, azoles and nikkomycin Z defungal therapy for patients with persistent fever and monstrate additive effects of micafungin and vorineutropenia. Of note, patients who received cas-conazole/caspofungin versus Aspergillus spp., [57] in pofungin had greater survival (93% vs 89%), im-vitro additivity or indifference when combined with proved response to therapy of baseline invasive fun-voriconazole versus filamentous fungi, [58] and in gal infections (52% vs 26%), less nephrotoxicity vitro synergy when micafungin is combined with (3% vs 12%), less infusion-related toxicity (35% vs nikkomycin Z against Aspergillus fumigatus.
[59] 52%) and fewer drug-related adverse events (54% vs 69%). [49] In Vivo Activity
Micafungin has been extensively studied in
Clinical Safety animal models of invasive fungal infection, includCaspofungin is generally well tolerated with few ing severely immunocompromised animals. Activireported adverse events and an overall profile comty has been demonstrated in models of disseminated parable with fluconazole and appreciably more faazole-resistant C. albicans in mice, pulmonary asvourable than amphotericin B deoxycholate. [48] pergillosis in neutropenic rabbits and temporarily Symptoms due to histamine release, possibly related neutropenic mice, as well as prophylaxis against to the fact that caspofungin is a basic polypeptide, P. jiroveci infection in mice. [60] [61] [62] [63] [64] In a comparative were seen in approximately 2% of patients in the study of in vivo efficacy and plasma pharmacoclinical trials. In the pivotal candidaemia trial, <3% kinetics of micafungin against disseminated candiof patients reported fever, flushing, nausea, headdiasis and invasive pulmonary aspergillosis in perache, vomiting and infusion-related reactions. [48] sistently neutropenic rabbits, in vivo efficacy was Abnormalities in serum transaminase levels were seen in both infections. However, concentrationseen at frequencies similar to those reported for and dose-dependent clearance of C. albicans was patients receiving fluconazole and more frequently seen while no significant microbiological clearance in patients receiving high doses of caspofungin and of A. fumigatus from lung tissue was observed in ciclosporin. [40] this model of invasive infection. Despite the lack of
Micafungin
clearance of A. fumigatus from tissue, the rabbits Micafungin is a water-soluble lipopeptide echi-with aspergillosis had improved survival and a renocandin derived from chemical modification of the duction in pulmonary infarction when treated with environmental mould Coleophoma empedri. Like micafungin. [63] This disparity between persistence of the other echinocandins in development, micafungin residual fungal burden in neutropenic hosts and imis available in intravenous formulation only. [37, 50] provement in survival is a general class effect of echinocandins where the hyphal structure is disruptIn Vitro Activity ed, growing cells are killed, but viable fungal eleMicafungin demonstrates fungicidal activity ments may persist. [32, 63, 65] against Candida spp., including isolates from severely ill immunocompromised patients and those
The combination of micafungin and ravuconaresistant to fluconazole and itraconazole, and poten-zole in a persistently neutropenic rabbit model of cy against clinical isolates of Aspergillus spp. [51] [52] [53] [54] [55] invasive aspergillosis demonstrated synergistic or Micafungin has little in vitro activity against additive activity of the combination versus single C. neoformans, Fusarium solani, P. boydii, agents by a range of study parameters: survival, residual fungal burden, pulmonary injury indices
The results of the first randomised, double-blind and galactomannan antigenaemia. [35] A study of mi-trial of micafungin were presented at the Intercafungin combined with itraconazole, amphotericin science Conference on Antimicrobial Agents and B or nikkomycin Z in a murine model of aspergillo-Chemotherapy (ICAAC) in San Diego, CA, USA, in sis demonstrated the efficacy of combination ther-September 2002. [76] In a large, international, collabapy, but no clear benefit versus therapy with ampho-orative study of micafungin 50 mg/day versus flucotericin B or itraconazole alone. [66] nazole 400 mg/day as prophylaxis for invasive fungal infections in patients undergoing haematopoietic
Pharmacokinetics and Tissue Distribution stem cell transplantation, success, defined as the Like caspofungin, micafungin has poor oral bio-absence of fungal infection for 4 weeks following availability and is only available in an intravenous study therapy, was seen in 80% of micafunginformulation. The volume of distribution is small at compared with 73.5% of fluconazole-treated pa-0.2-0.27 L/kg in adults and micafungin is highly tients. This difference was significant in favour of protein bound (>99%). [67, 68] Pharmacokinetics are micafungin. Micafungin recipients required less emlinear and t 1 /2β ranges from 3 to 6 hours in animals pirical therapy and, importantly, developed fewer and 10 to 15 hours in humans. [68, 69] Micafungin is infections due to Aspergillus spp. during neutropenmetabolised by the liver, possibly by O-methyltrans-ia (one vs seven patients, p = 0.07 in favour of ferase, with a small amount excreted renally. [68] A micafungin). The median duration of therapy in this phase I study demonstrated that no dosage adjust-study was 18 days in both arms and the overall ment is needed in patients with severe renal fail-safety profile was comparable between these agents, ure. [70] with increased bilirubin, nausea and diarrhoea as the three most commonly reported drug-related adverse Clinical Efficacy events in both arms. Micafungin has been studied in two open-label, Micafungin has been studied in children in a dose-ranging studies of endoscopically proven oedose-ranging study of empirical therapy of persistsophageal candidiasis in HIV patients in South Afriently febrile children aged 2-17 years. [69] In this ca and South America at dosages of 12.5-100 mg/ study, micafungin was well tolerated to dosages of day. In these studies, a dose response was seen, with 3.0 mg/kg/day. The plasma pharmacokinetic profile clinical success documented in 92% or more of the of micafungin in children is similar to that in adults. subjects treated with 50mg or higher (endoscopic To date, micafungin has been studied over a documentation of resolution at 75 or 100 mg/day; range of dosages and demonstrated efficacy as prosafety okay up to 21 days at 100 mg/day). [71, 72] Anphylaxis at 50 mg/day, while higher doses of other international, double-blind, comparative study 100-150 mg/day seem necessary to treat oeof several different dosages of micafungin (50, 100, sophageal candidiasis, apparently related to the need 150 mg/day) versus fluconazole 200 mg/day in the to penetrate the oesophageal lumen. Further dosetreatment of HIV-positive patients with oesophageal ranging studies are needed in order to define the candidiasis showed similar endoscopic cure rates optimal dosage of micafungin. (endoscopy grade 0) and safety profiles for micafungin at doses of 100 and 150 mg/day and flucoClinical Safety nazole. [73] In open-label studies of patients with deep fungal Micafungin has a similar safety profile to that of infections (candidiasis or aspergillosis) in Japan, caspofungin. In several studies, the most commonly 92% had clinical success following a mean of 22 reported adverse events included nausea, vomiting, days of therapy with varying dosages of mi-increased bilirubin levels and increases in liver funccafungin. [74] A single-centre US study of micafungin tion tests. [69, 71, [74] [75] [76] Histamine-related reactions, reat dosages of 50-150 mg/day with or without other ported with caspofungin, have not been frequent in antifungal therapy, in the treatment of 14 oncology these initial studies of micafungin. In addition, the patients with candidaemia demonstrated success in adverse interaction between caspofungin and 11 of 12 patients (92%). [75] ciclosporin was not observed for micafungin. [76] 
Anidulafungin
In neutropenic immunocompromised rabbits, Anidulafungin is the third echinocandin in devel-anidulafungin therapy led to improved survival and opment currently under regulatory review. Like cas-decreased lung injury when used as prophylaxis or pofungin and micafungin, anidulafungin is available therapy for invasive pulmonary aspergillosis. [65] in the parenteral formulation only.
Anidulafungin reduced the residual fungal burden and prolonged survival against both amphotericin
In Vitro Activity B-susceptible and -resistant invasive A. fumigatus Anidulafungin has broad-spectrum antifungal ac-infection in a neutropenic mouse model. [85] In a tivity with demonstrated in vitro potency against comparative study with ravuconazole in immunoyeasts, including fluconazole-resistant Candida iso-suppressed rabbits, anidulafungin therapy was assolates, dimorphic fungi and moulds including Asper-ciated with improved survival and decreased aspergillus spp. [16, 26, [77] [78] [79] [80] Of note, anidulafungin is not gillus antigenaemia, but did not eliminate organisms active against C. neoformans, a fungus that has a from tissue. [86] different composition of glucan polymer with preIn all of these animal models of invasive fungal dominant β 1,6-linkage, or against B. dermatitidis infection, the elimination of hyphae is influenced by because of greater cellular reliance upon α-1,3 D the number of neutrophils, monocytes and macroglucan instead of β linkage. [81] phages. The more profoundly compromised the host In vitro synergy testing with voriconazole and animal, the greater the residual fungal burden. itraconazole demonstrated synergy with anidulafungin against Aspergillus spp. and indifference
Pharmacokinetics and Tissue Distribution
against Fusarium spp. [82] Like caspofungin and micafungin, anidulafungin
In Vivo Activity has poor oral bioavailability and is only available in Anidulafungin has been studied in a number of an intravenous formulation. In studies in rabbits, animal studies, including models of invasive candi-anidulafungin demonstrated linear pharmacodiasis and aspergillosis. In a comparative in vivo and kinetics, peak plasma concentrations greater than pharmacokinetic study with amphotericin B deoxy-the MIC values reported for most susceptible fungal cholate in a model of fluconazole-resistant oro-pathogens and a large volume of distribution sugpharyngeal and oesophageal candidiasis in immuno-gesting extensive distribution into tissues. These compromised rabbits, anidulafungin demonstrated studies documented tissue concentrations in lung, dose-and concentration-dependent fungicidal ac-liver, spleen, kidney and brain. [87] tivity in the tongue, oropharynx, oesophagus, stomIn human volunteers, anidulafungin exhibits lineach and duodenum. [83] Anidulafungin was superior ar pharmacokinetics after single oral doses of to amphotericin B and fluconazole in clearing 100-1000mg. Peak plasma concentrations in that C. albicans from all tissues studied and was well study occurred 6-7 hour after ingestion and the t 1 /2β tolerated with no observed elevations in liver funcwas approximately 30 hours. The drug was well tion tests, electrolytes or renal parameters. In this tolerated at doses of up to 700mg, with adverse study, anidulafungin demonstrated a linear and gastrointestinal effects defining the maximum tolerdose-proportional plasma and tissue pharmacokineated dose. [88] With the long plasma half-life, oncetic profile. [83] An earlier in vivo and pharmacokinetic daily dose administration is anticipated. study compared anidulafungin with amphotericin B
A population pharmacokinetic analysis of anidudeoxycholate in a persistently neutropenic rabbit lafungin in patients with candidiasis or aspergillosis model of disseminated invasive candidiasis. In this demonstrated predictable plasma pharmacokinetics setting, anidulafungin was as effective as amphowith low between-subject variability. The results tericin and fluconazole in the treatment of dissemisuggest that no dosage adjustment of anidulafungin nated invasive candidiasis. It also demonstrated is required on the basis of age, weight, gender, dose-dependent clearance of C. albicans from tisethnicity, HIV infection, fungal disease status or the sues, including brain, and linear plasma pharmacouse of concomitant medications. [89] kinetics. [84] Clinical Efficacy clinical trials. Case reports and small uncontrolled Anidulafungin demonstrated equivalent efficacy studies have been published for posaconazole, but as to fluconazole in endoscopically and mycologically yet no clinical data are available for ravuconazole. proven oesophageal candidiasis in a randomised, Like the earlier azoles, these newer agents act via double-blind, international multicentre study with inhibition of fungal CYP-dependent lanosterol success documented in 242 of 249 evaluable anidu-14-α-demethylase. [9, 37] lafungin patients (97.2%) and 252 of 255 fluconaVoriconazole and ravuconazole are structurally zole patients (98.8%), although more fluconazole related to fluconazole, while posaconazole is similar patients had sustained responses. Treatment-related in structure to itraconazole (figure 2). All three adverse events were reported in 10% of anidula-drugs are available orally, and voriconazole and fungin patients and 13% of fluconazole patients. [90] ravuconazole have intravenous formulations or proIn a noncomparative dose-ranging study of drugs. Like the earlier azoles, these three drugs have anidulafungin 100mg loading dose followed by been associated with varying degrees of drug inter-50 mg/day, 150mg loading dose followed by 75 mg/ actions and hepatotoxicity. day, and 200mg loading dose followed by 100 mg/
Voriconazole
day for candidaemia, successful global response was Voriconazole was developed from fluconazole seen in 83-92% of patients at end of therapy, by substituting a fluoropyrimidine ring for one of 72-86% of patients at test-of-cure (2 weeks after the azole groups to enhance the spectrum, and adend of therapy) and reported adverse events were ding an α-methyl group to provide fungicidal acsimilar to those seen in the general population. [91] A tivity against Aspergillus spp. and other moulds. [92] phase III study of anidulafungin in the treatment of Voriconazole was studied in humans for 10 years candidaemia is ongoing.
between the first human study in 1991 and its US FDA approval in December 2001. A broad-spec-2. Antifungals Targeting Cell Membrane trum azole, voriconazole was studied in >1000 patients with infections due to Aspergillus spp., Candi-
Triazole Antifungals
da spp., as well as a number of less common yeasts and moulds. [92] The azole antifungal agents in clinical use for systemic treatment contain either two or three nitroIn Vitro Activity gen atoms in the azole ring and, thereby, are classiVoriconazole has broad in vitro antifungal acfied as imidazoles (ketoconazole and miconazole) or tivity against yeasts and moulds, with demonstrated triazoles (itraconazole and fluconazole), respective-activity against the most frequently isolated opporly. Azole antifungal agents inhibit the synthesis of tunistic pathogens, common dermatophytes and the ergosterol, the major sterol component in the fungal fungi that cause endemic mycoses. [92] [93] [94] [95] [96] Of note, plasma membrane, by interfering with the CYP-voriconazole has no activity against the agents of dependent enzyme lanosterol demethylase.
zygomycosis. [97] [98] [99] Voriconazole shows fungicidal activity in vitro 2.2 Newer Azole Antifungals against multiple Aspergillus spp., including A. terThe newer azoles were developed to expand the reus which is inherently resistant to amphotericin spectrum activity of existing azoles, namely fluco-B. [98, [100] [101] [102] [103] [104] [105] [106] In a comparative study with amphonazole or itraconazole, and provide fungicidal ac-tericin B, voriconazole demonstrated better fungicitivity versus mould, as well as to improve on some dal activity against A. fumigatus hyphae.
[107] There of the limitations of these drugs, namely gastrointes-are several definitions of in vitro fungicidal activity tinal toxicity and variable absorption for itracona-and its significance is not clear. Against Candida zole ( figure 2) .
spp., voriconazole is 60-to 100-fold more potent Voriconazole is the only US FDA-approved than fluconazole and has activity against non-albisecond-generation triazole, while posaconazole cans Candida spp., including C. krusei that are (SCH 56592) and ravuconazole are advancing in inherently resistant to fluconazole. [98, [108] [109] [110] [111] In vitro studies also demonstrate the activity of plasma pharmacokinetics in guinea pigs are closest voriconazole against the fungi that cause endemic to those in humans. In an early study of voriconazole mycoses (C. immitis, H. capsulatum, B. dermati-versus itraconazole in endocarditis, voriconazole tidis, Paracoccidioides brasiliensis). [112] Vori-was superior to itraconazole in both the prevention conazole is also active against the less common but and treatment of left-sided A. fumigatus endocardiincreasingly important emerging fungal pathogens tis.
[118] More recently, Kirkpatrick et al. [119] perincluding Scedosporium apiospermum, S. prolififormed studies in immunosuppressed guinea pigs cans, P. boydii (asexual form of S. apiospermum), with lethal invasive aspergillosis where voriTrichosporon spp., Acremonium kilensii and Fusariconazole was associated with improved survival and um spp. [98, [113] [114] [115] [116] [117] significant reduction in tissue burden of A. fumi-
In Vivo Activity
gatus. In a study of disseminated C. krusei infection Voriconazole has demonstrated efficacy in in neutropenic guinea pigs, voriconazole was assoanimal models of pulmonary, disseminated and inciated with significantly greater clearance of yeast travascular (including endocarditis) fungal infecfrom the important target organs of brain, liver and tion. The guinea pig is the animal best suited for in vivo pharmacokinetic studies of voriconazole as the kidney. [120] 
Pharmacokinetics and Tissue Distribution
In children, voriconazole pharmacokinetics appear to be linear to doses of 4 mg/kg every 12 hours. [123] Oral voriconazole is rapidly absorbed with maxiVariability between individuals in plasma vorimum plasma concentrations (Cmax) achieved 1-2 conazole concentration is high, while within indihours after dose administration in the fasted state. viduals variation is low. Several factors are likely to The oral bioavailability is 96%, thus allowing contribute to this variability. [92] switching between intravenous and oral formula-CYP2C19 plays a major role in voriconazole tions. Administration with high-fat meals resulted in metabolism and demonstrates genetic polymorreduced plasma concentrations, so oral dose adminphism with individuals of oriental descent having a istration is recommended either 1 hour before or 1 greater likelihood of being poor metabolisers. [92] hour after meals. [92] As voriconazole is a substrate for CYP2C19, 2C9 The volume of distribution of voriconazole is and 3A4, multiple drug interactions are likely. Table  estimated to be 4.6 L/kg, suggesting extensive dis-II and table III outline the key data and recommentribution into tissues. [92] Plasma protein binding is dations regarding voriconazole drug interactions. moderate at 58%. [92] Voriconazole has been detected The recommended dose administration regimen in brain, liver, kidney, heart, lung and spleen of for voriconazole is a standard loading dose of 6 mg/ autopsy specimens as well as the CSF of patients in kg intravenously every 12 hours for two doses folconcentrations approximately 50% that observed in lowed by 4 mg/kg intravenously every 12 hours for plasma but still at multiples of trough concentrathe treatment of invasive aspergillosis or other invations. [37, 92] In a comparative study in uninfected sive mould infections with the option to step down rabbits, voriconazole demonstrated prominent disto oral therapy at 400mg twice daily. This regimen is tribution into pulmonary epithelial lining fluid, based on the pivotal clinical study in invasive asperwhereas liposomal amphotericin B demonstrated an gillosis where oral step-down therapy was allowed even distribution of amphotericin B into lung tissue, after a minimum of 7 days of intravenous therepithelial lining fluid and pulmonary alveolar apy. [125] In Europe, voriconazole is also indicated for macrophages. [121] the treatment of refractory candidal infections, inMetabolism is hepatic, primarily via N-oxida-cluding C. krusei. tion. The major metabolite, the N-oxide, has no Dose adjustment is needed for patients with antifungal effect and is not believed to contribute to chronic hepatic impairment. A phase I study in efficacy. Voriconazole is metabolised via several patients with Child-Pugh A and B cirrhosis led to the hepatic CYP isoenzymes, including CYP2C19, recommendation to give the standard loading doses CYP2C9 and CYP3A4. [92] followed by half the daily maintenance dose in these As voriconazole has limited aqueous solubility, patients. Patients with severe hepatic cirrhosis have the intravenous formulation was prepared using a not been studied. Importantly, this recommendation solubilising excipient, sulfobutylether-β-cyclodex-does not apply to patients with acute hepatic injury. trin (SBECD). Because of potential concerns of Patients with acute injury as a result of graft-versusnephrotoxicity and accumulation in plasma, the par-host disease, veno-occlusive disease and haemoenteral solution of SBECD is not recommended in dynamic hepatic injury were included in the pivotal patients with a glomerular filtration rate <50 mL/ and compassionate/emergency use voriconazole min. [92] studies. [92] On the basis of these data, standard dose administration is recommended for these individuVoriconazole pharmacokinetics are nonlinear in als. adults with a greater than proportional increase in plasma concentration with dose escalation. [122] PlasNo adjustment of oral voriconazole is needed in ma steady state is achieved at approximately day 6 individuals with renal dysfunction as voriconazole of therapy, but plasma concentrations close to is metabolised by the liver. The intravenous formusteady state are attained within 24 hours when a lation is solubilised in SBECD that is renally excretloading dose regimen of 6 mg/kg intravenously or ed and accumulates in individuals with moderate 400mg orally every 12 hours for two doses is used. renal impairment, as defined by a creatinine clear- Adjustment of vinca alkaloid dosage may be needed AUCτ = area under the concentration-time curve over the dose administration interval; Cmax = maximum concentration; CYP = cytochrome P450; INR = international normalised ratio; NNRTI = non-nucleoside reverse transcriptase inhibitor.
ance of <50 mL/min. In a study of parenteral vori-(mean of two; 83% had received previous azole conazole in patients with moderate renal dysfunc-therapy). In this population, voriconazole was assotion (creatinine clearance of 30-50 mL/min), the ciated with a 56% complete or partial success rate AUC τ (area under the concentration-time curve over following a mean duration of therapy of 60 days. [130] the dose administration interval, here 12 hours) and A randomised comparative study of voriconazole Cmax of SBECD increased by 4-fold and 50%, re-versus amphotericin B deoxycholate followed by spectively, compared with controls. [126] Thus, oral fluconazole for treatment of candidaemia in nonvoriconazole is recommended preferentially in indi-neutropenic patients has completed and data are viduals with renal impairment unless the benefits of expected in 2004. Results of voriconazole therapy in therapy outweigh the potential risks. [92, 126] a series of 11 HIV-infected patients from Thailand with P. marneffei infection demonstrated success in Clinical Efficacy eight of nine evaluable patients and no discontinuaVoriconazole has been studied in the treatment of tions as a result of adverse events.
[141] a number of invasive fungal infections with efficacy Voriconazole has demonstrated efficacy in clindocumented in case reports and clinical trials of ical trials of invasive aspergillosis. [124, 125, 128] In a invasive yeast and mould infections including prospective, international, randomised open-label aspergillosis, [124, 125, 127, 128] candidiasis, [124, 129, 130] scetrial of voriconazole versus amphotericin B deoxydosporiosis and pseudallescheriasis, [124, [131] [132] [133] [134] [135] [136] paecholate followed by other licensed antifungal thercilomycosis, [137] fusariosis, [124, 138, 139] coccidapy, patients treated with voriconazole experienced ioidomycosis, [140] cryptococcosis [124] and other ensuperior success rates and a 22% relative survival demic mycoses. [124] Voriconazole has also been benefit. [125] In this study, voriconazole was well studied in invasive fungal infections in children. [123] tolerated with significantly fewer severe drug-relatIn a double-blind, double-dummy, international ed adverse events. Lewis and colleagues [142] recently comparative study of voriconazole versus fluconapresented data on the pharmacoeconomic impact of zole for the treatment of endoscopically proven oethis treatment strategy. The cost of other licensed sophageal candidiasis in AIDS patients, voriantifungal therapies accounted for 96% of the total conazole was as effective as fluconazole, although drug costs and was higher in the amphotericin Bvoriconazole patients experienced more liver-relattreated patients ($US794 328 vs $US202 176 for ed adverse events. [129] Ostrosky-Zeichner et al. [130] voriconazole patients). They found a total drug cost reported on 52 patients who received voriconazole per treatment success of $US19 409 for amphoas salvage therapy for invasive candidiasis, most of tericin B compared with $US10 262 for voriwhom had documented progression of disease, had previously received multiple antifungal agents conazole (2003 values) . [142] Table III. Effect of other drugs on voriconazole pharmacokinetics [61, 124] CYP induction inhibition of voriconazole metabolism and toxicity related to voriconazole (increased plasma voriconazole exposure) AUCτ = area under the concentration-time curve over the dose administration interval; Cmax = maximum concentration; CYP = cytochrome P450.
A retrospective series of five patients with docu->3 months, 30 patients lived >1 year). [145] Another mented invasive aspergillosis treated with combina-small study of 19 patients with documented bone tion voriconazole and caspofungin demonstrated aspergillosis demonstrated success (complete or efficacy with responses in all five, and no deaths partial response) in 10 of 19 patients (52%) and an attributable to aspergillosis. Companion in vitro acceptable safety profile. [146] studies showed additive interactions by fractional
In a large international collaborative study of inhibitory concentration indices. [143] voriconazole versus liposomal amphotericin B for A retrospective survey of invasive aspergillosis empirical therapy, voriconazole did not meet the due to A. terreus compared voriconazole with other prespecified statistical endpoint for non-inferiority systemic antifungal therapy, mostly with ampho-in a composite endpoint but was associated with tericin B formulations, in terms of survival at 12 significantly fewer breakthrough invasive fungal inweeks.
[144] In this group, 30 of 83 survived (36%); fections, particularly invasive aspergillosis.
[147] In a 16 of 34 voriconazole patients (47%) and 14 of 49 prespecified secondary efficacy analysis, voripatients (29%) who received other antifungal ther-conazole was comparable with liposomal amphoapy, thus supporting the role of voriconazole in tericin B and resulted in a significant reduction of treating infections due to A. terreus. [144] Troke et invasive fungal infections among high-risk neutroal. [145] presented the results of a large retrospective penic patients. This study has been the focus of study (n = 86) of voriconazole therapy in document-debate over the design of empirical therapy ed CNS invasive aspergillosis at the 43rd ICAAC, trials. [106, [148] [149] [150] Marty and colleagues [151] reported Chicago, IL, USA, in September 2003. In this heavi-on the development of breakthrough zygomycosis in ly pretreated population (96% patients received a 4 of 24 allogeneic bone marrow or stem cell transmedian 31 days of prior systemic antifungal ther-plant patients (3%) receiving voriconazole as empirapy), success (complete or partial response) was ical antifungal therapy or prophylaxis between Sepseen in 35% and survival in 31% (22 patients lived tember 2002 and June 2003. Of note, only two cases of zygomycosis were recorded in the same institu-voriconazole concentrations. [153] Retrospective clintion in the 2 years prior to the availability of vori-ical data from 16 liver transplant patients treated conazole. This correlates with the lack of in vitro with voriconazole as salvage therapy for invasive activity of voriconazole against zygomycetes and fungal infections demonstrate that voriconazole is emphasises the importance of pursuing diagnosis of well tolerated in this population, with a median resistant fungal infections in patients at continued duration of therapy of 49 days (range 7-439 days), risk. [151, 152] few discontinuations (3 of 16, two of which were treatment related) and is associated with successful outcomes in 9 of 16 patients (56%). [154] Clinical Safety
Skin rashes were reported in 19% of patients Voriconazole is well tolerated, as demonstrated treated in the voriconazole clinical studies. Most by its improved tolerability compared with amphowere mild and rarely led to discontinuation. Several tericin B deoxycholate and liposomal amphotericin cases of severe skin reactions, including Stevens-B. [125, 147] Three specific safety concerns should be Johnson syndrome and toxic epidermal necrolysis considered: visual adverse events; liver function test were reported. In addition, reports have been made abnormalities; and skin reactions.
about photosensitivity reactions in patients receivVisual adverse events are the most frequent ading voriconazole. [155] The mechanism is unclear as verse events associated with voriconazole exposure.
neither voriconazole nor its major metabolite deApproximately 30% of healthy volunteers or pamonstrate absorption in the UVA spectrum. Patients tients experience visual adverse events when exshould be advised to avoid sun exposure during posed to either oral or intravenous voriconazole.
voriconazole therapy. Most individuals report transient altered perception of light, photopsia, chromatopsia or photophobia.
Posaconazole
The visual events typically begin approximately 30 Posaconazole was developed from itraconazole minutes after dose administration and last about 30 and, like the other second-generation triazoles, has a minutes. They tend to be reported early in therapy, broad spectrum of activity against yeasts and with few patients reporting events after several days moulds. Of note, posaconazole has in vitro, in vivo of therapy. The events are mild and led to discontin-and clinical efficacy in treatment of infections due to uation in <1% of patients treated in the clinical zygomycetes, organisms for which there are currentdevelopment programme. [92] Abnormalities in elec-ly limited options. Unlike the other azoles, posacotroretinograms occur with voriconazole therapy, nazole is only available in an oral formulation and persist for the duration of therapy (studied for 28 requires frequent dose administration. days) and completely reverse within 2 weeks of discontinuation of therapy. [92] In Vitro Activity Posaconazole demonstrates potent in vitro acHepatic enzyme abnormalities are the dose-limittivity against Candida spp. (including clinical isoing adverse event for voriconazole and occur in lates and non-albicans species), Aspergillus spp., 12-20% of patients treated with voriconazole. [92] Scedosporium spp., Fusarium spp., C. neoformans, Abnormalities of alanine aminotransferase and asCoccidioides spp., Histoplasma spp., Trichosporon partate aminotransferase are most frequent, but elespp. and many other yeasts, moulds and demavations of alkaline phosphatase and total bilirubin tiaceous moulds. [95, 96, 113, [115] [116] [117] [156] [157] [158] [159] [160] [161] have also been reported. Enzyme abnormalities have been seen to normalise in the face of continued dose Like voriconazole, posaconazole demonstrates in administration or upon discontinuation of vori-vitro fungicidal activity against Aspergillus spp.
[ 100] conazole, but serious events including hepatic fail-Importantly, posaconazole also demonstrates acure and death have been reported. Thus, current tivity against zygomycetes. [97, 99] In comparative recommendations include routine monitoring of studies, posaconazole was more potent than vorihepatic enzymes during therapy. Pharmacokinetic conazole, fluconazole, itraconazole, and is at least as analyses show that the risk of developing hepatic potent as amphotericin B, distinguishing it from all enzyme elevations increases with increasing plasma available azoles.
In Vivo Activity adults was well tolerated and demonstrated dosePosaconazole has demonstrated activity in a proportional AUC between 50 and 800mg. [170] Satunumber of animal models of invasive fungal infec-ration of absorption was observed at doses above tion. In rabbit models of invasive aspergillosis, in-800mg, presumably because of the poor solubility of cluding A. terreus, an organism inherently resistant posaconazole. to amphotericin B, posaconazole was associated
The apparent volume of distribution is large with improved survival, decreased severity of pul-(343-1341L) with a long-terminal phase t 1 /2 (25-31 monary infection, significantly decreased tissue bur-hours), suggesting extensive distribution in to den of Aspergillus spp., as well as decreases in tissues and supporting once or twice daily dose galactomannan antigenaemia. [162] [163] [164] Compared administration.
[170] A human case report documentwith itraconazole and amphotericin B in a model of ed presence of posaconazole in vitreous fluid (plasinvasive pulmonary A. fumigatus infection in neu-ma concentration 1.2 μg/mL, vitreous concentration tropenic rabbits, posaconazole was associated with 0.25 μg/mL). [171] significantly greater survival, reduction in pulmonBioavailability of posaconazole increases with ary injury, lower residual fungal burden and lower high-fat meals or nutritional supplements: Cmax inlevels of galactomannan antigenaemia than was itra-creased 3.4-fold and AUC 2.6-fold with Boost conazole at similar dosages and plasma concentra-Plus™ 1 . [172] Posaconazole interacts with tacrolimus, tions. [163] Administered in combination, posacona-causing increased tacrolimus Cmax (2.2-fold) and zole and caspofungin demonstrated survival greater AUCτ (4.5-fold); this is likely to be because of the to that seen with each single agent in an immuno-inhibition of CYP3A4 metabolism and P-glycoprocompetent mouse model of invasive aspergillo-tein transport of tacrolimus by posaconazole. [173] sis. [165] Posaconazole was compared with itraconazole Clinical Efficacy and amphotericin B in a neutropenic mouse model Posaconazole capsules and suspension demonof zygomycosis using three clinical Mucor isolates. strated comparable efficacy to fluconazole in phase In this setting, posaconazole demonstrated a dose-II studies of oesophageal candidiasis. [174, 175] In an dependent survival advantage and decrease in open-label, noncomparative, multicentre study of residual tissue fungal burden compared with itra-posaconazole as salvage therapy for invasive fungal conazole, which was associated with survival and infections, posaconazole was associated with sucresidual tissue fungal burden similar to that of con-cess at week 4 in 8 of 15 patients with invasive trol animals. At the doses tested, posaconazole was aspergillosis (53%), three of four patients with cancomparable with amphotericin B in terms of survi-didiasis, three of four patients with fusariosis and val and efficacy. [166] seven of ten patients with infections due to other In other models, posaconazole demonstrated effi-fungal pathogens.
[176] Posaconazole demonstrated cacy in treatment of P. boydii, histoplasmosis (survi-success in 9 of 21 patients (43%) treated for refracval advantage compared with itraconazole and tory invasive fungal infections in a recently presentamphotericin B in a T-cell-depleted mouse model) ed open-label pharmacokinetic study. [177] In a multiand cryptococcosis (survival advantage, decreased centre study of posaconazole therapy for chronic tissue burden compared with amphotericin in brain pulmonary or nonmeningeal disseminated coctissue in mouse model). [156, 158, 167, 168] cidioidomycosis, 15 of 20 patients completed ≥23 weeks of therapy. [178] Pharmacokinetics and Tissue Distribution
In a healthy volunteer study of posaconazole in An open-label study of posaconazole as salvage the fasted state, splitting the dose significantly in-therapy for fungal infections of the CNS (n = 49) creased exposure. Thus, the current recommended demonstrated success in 40% of patients with brain dose is 200mg orally four times each day. [169] Posa-infection due to filamentous fungi and 59% of those conazole in single and multiple doses in healthy with HIV-associated cryptococcal meningitis.
[179]
1 The use of trade names is for product identification purposes only and does not imply endorsement. and Trichosporon spp., as well as other yeasts and therapy. [180] Results of an open-label, uncontrolled moulds. [96, 117, [187] [188] [189] [190] [191] Like voriconazole, ravuconastudy of posaconazole as salvage therapy for invazole is fungicidal in vitro against Aspergillus sive fungal infections in patients with chronic granuspp. [100] Ravuconazole is active against S. apioslomatous disease demonstrated complete response permum, [113] but less potent against Fusarium in six of seven patients refractory to (n = 6) or spp.
[116] intolerant of (n = 1) previous voriconazole therapy. [181] In Vivo Activity
Among seven patients with histoplasmosis
Ravuconazole demonstrates activity in experirefractory to or intolerant of licensed antifungal mental models of infections due to Candida, Aspertherapy, posaconazole as salvage therapy was asso-gillus and Cryptococcus spp., including in immunociated with success in six, including one with docu-compromised models. [192] [193] [194] Efficacy was better mented CNS histoplasmosis and stable disease in than anidulafungin in a comparative rabbit model of one. [182] Posaconazole has been reported to be effec-disseminated aspergillosis where improved survival tive in cases of Acremonium strictum pulmonary and decreased Aspergillus antigenaemia were obinfection failing amphotericin B, [183] S. apios-served, along with an elimination of organisms from permum brain abscess failing therapy with ampho-tissue.
[86] In a model of invasive pulmonary aspertericin B and ketoconazole, [184] ocular and systemic gillosis due to A. fumigatus in persistently neutroinvasive F. solani infection of the eye, [171] and penic rabbits, ravuconazole demonstrated signifmucormycosis in a heart-kidney transplant pa-icant dose-dependent improvement in survival, and tient.
[185] In a series of 13 patients with chronic reduction in residual tissue fungal burden, pulmonindolent infections with mycetoma (n = 7) or ary injury, and decrease in organisms recovered by chromoblastomycosis (n = 6) refractory to or intol-bronchoalveolar lavage and serum galactomannan erant of standard therapy, posaconazole was tolerat-index compared with untreated controls. [195] ed for long durations (>6 months in ten patients, >1
Pharmacokinetics and Tissue Distribution year in five patients) and success was documented in
In humans, ravuconazole has been studied in 11 of 15 patients (73%). [186] single-and multiple-dose studies in healthy volun-
Clinical Safety
teers. In these settings, ravuconazole was well tolerIn comparative studies versus fluconazole for the ated to dosages of 800mg once daily or 400 mg/day treatment of oesophageal candidiasis, posaconazole for 14 days. [196, 197] Single parenteral doses of was not associated with any increased or different 25-600mg BMS-379224, the water-soluble prodrug adverse events. [175] In a noncomparative multicentre of ravuconazole, were well tolerated, demonstrated study of posaconazole as salvage therapy for inva-rapid conversion to ravuconazole and linear plasma sive fungal infections, the most commonly reported pharmacokinetics. [198] adverse events were diarrhoea, asthenia, flatulence and eye pain. [176] 3. Future Directions
Ravuconazole
The last few years have seen the availability of Ravuconazole is a derivative of fluconazole with several new antifungal agents that provide increased an expanded spectrum of activity in vitro. It is efficacy and safety to immunosuppressed patients. available in oral form. A di-lysine phosphoester The echinocandins and second-generation triazole prodrug has been developed to facilitate intravenous antifungal agents bring new choices and advances in administration.
our ability to treat invasive yeast and mould infec- 
